Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
Avalon GloboCare Corp. (NASDAQ: ALBT) has announced the launch of a direct-to-consumer DNA test for opioid addiction predisposition through its 40% owned Laboratory Services MSO. The DNA4Addiction test analyzes 15 genetic markers linked to opioid dependence, categorizing individuals into risk levels. This non-invasive, at-home test comes amid the ongoing opioid crisis, with opioids involved in over 75% of nearly 107,000 drug overdose deaths in 2022.
The test aims to provide insights for proactive health management, though it is not a diagnosis. It examines factors such as neurotransmitter activity and substance sensitivity. Dr. David Jin, CEO of Avalon, emphasized the importance of recognizing genetic predisposition for early intervention. Bob Forrest, Brand Ambassador for DNA4Addiction, highlighted its potential in guiding lifestyle changes and preventing addiction, especially for parents concerned about their children's risks.
Avalon GloboCare Corp. (NASDAQ: ALBT) ha annunciato il lancio di un test del DNA diretto al consumatore per la predisposizione all'addiction da oppioidi attraverso il suo Laboratorio Servizi MSO di cui possiede il 40%. Il test DNA4Addiction analizza 15 marcatori genetici collegati alla dipendenza da oppioidi, classificando gli individui in base ai livelli di rischio. Questo test non invasivo, da eseguire a casa, arriva in un contesto di crisi legata agli oppioidi, che nel 2022 hanno contribuito a oltre il 75% dei quasi 107.000 decessi per overdose da droga.
Il test mira a fornire informazioni per una gestione della salute proattiva, anche se non equivale a una diagnosi. Esamina fattori come l'attività dei neurotrasmettitori e la sensibilità alle sostanze. Il dottor David Jin, CEO di Avalon, ha evidenziato l'importanza di riconoscere la predisposizione genetica per un intervento precoce. Bob Forrest, Brand Ambassador di DNA4Addiction, ha sottolineato il suo potenziale nell'orientare i cambiamenti di stile di vita e nel prevenire l'addiction, specialmente per i genitori preoccupati per i rischi dei propri figli.
Avalon GloboCare Corp. (NASDAQ: ALBT) ha anunciado el lanzamiento de una prueba de ADN directa al consumidor para la predisposición a la adicción a opioides a través de su Laboratorio Servicios MSO, en el que posee el 40%. La prueba DNA4Addiction analiza 15 marcadores genéticos vinculados a la dependencia de opioides, clasificando a las personas en niveles de riesgo. Esta prueba no invasiva, que se realiza en casa, se presenta en medio de la crisis de opioides, que estuvo involucrada en más del 75% de casi 107,000 muertes por sobredosis de drogas en 2022.
El objetivo de la prueba es proporcionar información para una gestión proactiva de la salud, aunque no es un diagnóstico. Examina factores como la actividad de los neurotransmisores y la sensibilidad a sustancias. El Dr. David Jin, CEO de Avalon, enfatizó la importancia de reconocer la predisposición genética para intervenir temprano. Bob Forrest, Embajador de Marca de DNA4Addiction, destacó su potencial para guiar cambios en el estilo de vida y prevenir la adicción, especialmente para los padres preocupados por los riesgos de sus hijos.
Avalon GloboCare Corp. (NASDAQ: ALBT)은 40% 소유한 실험실 서비스 MSO를 통해 소비자 직접 DNA 검사를 통한 오피오이드 중독 경향 검사를 출시한다고 발표했습니다. DNA4Addiction 검사는 오피오이드 의존성과 관련된 15개의 유전 마커를 분석하여 개인을 위험 수준으로 분류합니다. 이 비침습적인 자가 테스트는 2022년 거의 107,000건의 약물 과잉복용 사망의 75% 이상이 오피오이드와 관련된 가운데 출시됩니다.
이 검사는 조기 개입을 위한 유전적 소인을 인식하는 것의 중요성을 강조한 Avalon의 CEO인 David Jin 박사처럼 건강 관리를 위한 통찰력을 제공하는 것을 목표로 합니다. DNA4Addiction의 브랜드 앰배서더인 Bob Forrest는 자녀의 위험을 걱정하는 부모에게 특히 중독 예방을 위한 생활 습관 변화 안내의 잠재력을 강조했습니다.
Avalon GloboCare Corp. (NASDAQ: ALBT) a annoncé le lancement d'un test ADN direct au consommateur pour la prédisposition à l'addiction aux opioïdes par l'intermédiaire de son laboratoire de services, dont il possède 40 %. Le test DNA4Addiction analyse 15 marqueurs génétiques liés à la dépendance aux opioïdes, classifiant les individus en niveaux de risque. Ce test non invasif à domicile arrive en plein milieu de la crise des opioïdes, avec des opioïdes impliqués dans plus de 75 % des près de 107.000 décès par surdose de drogue en 2022.
Le test vise à fournir des informations pour une gestion proactive de la santé, bien qu'il ne constitue pas un diagnostic. Il examine des facteurs tels que l'activité des neurotransmetteurs et la sensibilité aux substances. Le Dr. David Jin, PDG d'Avalon, a souligné l'importance de reconnaître la prédisposition génétique pour une intervention précoce. Bob Forrest, ambassadeur de la marque DNA4Addiction, a mis en avant son potentiel dans l'orientation des changements de mode de vie et la prévention de l'addiction, notamment pour les parents préoccupés par les risques encourus par leurs enfants.
Avalon GloboCare Corp. (NASDAQ: ALBT) hat die Einführung eines direkten DNA-Tests für die Neigung zur Opioidabhängigkeit über sein zu 40 % besessenes Labor Services MSO angekündigt. Der DNA4Addiction-Test analysiert 15 genetische Marker, die mit der Opioidabhängigkeit in Verbindung stehen, und kategorisiert Personen in Risikostufen. Dieser nicht-invasive Test, den man zu Hause durchführen kann, wird im Rahmen der anhaltenden Opioidkrise eingeführt, bei der über 75 % der fast 107.000 Überdosetoten im Jahr 2022 beteiligt waren.
Der Test soll Einblicke für eine proaktive Gesundheitsverwaltung geben, stellt jedoch keine Diagnose dar. Er untersucht Faktoren wie die Neurotransmitteraktivität und die Empfindlichkeit gegenüber Substanzen. Dr. David Jin, CEO von Avalon, betonte die Bedeutung, die genetische Veranlagung für eine frühzeitige Intervention zu erkennen. Bob Forrest, Markenbotschafter von DNA4Addiction, hob das Potenzial hervor, Lebensstiländerungen zu leiten und eine Sucht zu verhindern, insbesondere für Eltern, die sich um die Risiken ihrer Kinder sorgen.
- Launch of DNA4Addiction test kit for opioid addiction predisposition
- Potential for early intervention and prevention of opioid addiction
- Direct-to-consumer, non-invasive testing method
- Addresses a significant public health crisis (opioid epidemic)
- Potential revenue stream from 40% equity interest in Laboratory Services MSO
- Test results are not a diagnosis, potentially limiting clinical application
- Competitive market for genetic testing products
- Potential ethical concerns regarding genetic predisposition testing
The launch of DNA4Addiction by Laboratory Services MSO (LSM) represents a significant development in the field of personalized medicine and addiction prevention. This direct-to-consumer genetic test for opioid dependence predisposition could be a game-changer in addressing the ongoing opioid crisis.
The test analyzes 15 genetic markers associated with opioid dependence, which influence factors such as neurotransmitter activity and reward pathways. This approach aligns with current research in pharmacogenomics and addiction medicine. However, it's important to note that genetic predisposition is just one factor in addiction development and environmental and behavioral factors play significant roles as well.
While the test categorizes individuals into risk levels, it's important to emphasize that this is not a diagnostic tool. Rather, it provides information that could guide preventive strategies and inform medical decisions. The non-invasive, at-home collection method increases accessibility, potentially reaching a broader population for early intervention.
From a research perspective, widespread use of this test could contribute valuable data to the field of addiction genetics. However, ethical considerations around genetic testing and potential stigmatization should be carefully addressed. Future studies validating the test's predictive value and its impact on addiction prevention outcomes will be important to establish its clinical utility.
The launch of DNA4Addiction by LSM, in which Avalon GloboCare (NASDAQ: ALBT) holds a
The opioid crisis represents a substantial market opportunity. With over
However, investors should consider several factors:
- Market adoption rate and consumer acceptance of genetic testing for addiction risk
- Regulatory landscape for direct-to-consumer genetic tests
- Competition from established genetic testing companies and potential new entrants
- Long-term revenue model and pricing strategy
While the potential is promising, it's important to note that Avalon's
The introduction of DNA4Addiction comes at a critical juncture in the ongoing opioid crisis. With opioid-involved death rates increasing by
This genetic test offers a novel tool for risk assessment, potentially allowing for early intervention and personalized prevention strategies. However, its effectiveness as a public health measure will depend on several factors:
- Accessibility and affordability of the test for at-risk populations
- Integration with existing addiction prevention and treatment programs
- Public education about the test's capabilities and limitations
- Ethical use of genetic information in healthcare and addiction treatment settings
The endorsement by Bob Forrest, a recognized figure in addiction recovery, may help with public acceptance. However, it's important that the marketing and use of this test don't oversimplify the complex nature of addiction or lead to stigmatization.
From a public health perspective, while this test could be a valuable tool, it should be part of a comprehensive approach to addiction prevention that includes education, social support and evidence-based treatment options. The real impact of DNA4Addiction will be determined by how effectively it can be integrated into broader public health strategies to combat the opioid crisis.
Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection
FREEHOLD, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out more information, please visit www.dna4addiction.com. Avalon owns a
The opioid abuse epidemic continues to devastate communities across America, representing a significant public health crisis. According to the Centers for Disease Control and Prevention (CDC), the United States has experienced a dramatic rise in drug overdose deaths. In 2022, opioids were involved in over
DNA4Addiction offers a convenient home testing kit for customers to collect a DNA sample and send it for analysis. Researchers have identified 15 genetic markers linked to opioid dependence. These markers influence susceptibility to developing opioid dependence through factors such as neurotransmitter activity, reward pathways, and substance sensitivity. The test analyzes these markers to assess genetic predisposition to opioid dependence. For example, variations in neurotransmitter function, like dopamine, can affect the brain’s reward system and related behaviors. The results categorize individuals into High Risk, Moderate Risk, or Reduced Risk levels based on specific genetic variations. While this test is not a diagnosis, it provides valuable insights for proactive health management.
"Having a genetic predisposition to opioid dependence can significantly impact an individual’s susceptibility to excessive opioid use," stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "Though it is not a diagnosis or guarantee, genetic factors play a crucial role in shaping one’s response to opioids, influencing tolerance, drug reaction, and the likelihood of developing dependence. Recognizing this predisposition is essential for early intervention and prevention efforts. LSM has developed the DNA4Addiction testing kit to provide insights into an individual’s genetic predisposition to opioid addiction. Results from this kit can empower people to make informed decisions about their health and well-being. With this knowledge, individuals can take proactive steps to mitigate risk and seek appropriate support and resources."
Bob Forrest, Cofounder of Oro House Recovery Center and Brand Ambassador for DNA4Addiction, commented, “The opioid addiction crisis continues to escalate, making proactive measures more crucial than ever. DNA4Addiction equips individuals, especially parents, with the tools to understand addiction risks from a genetic perspective. This knowledge can guide necessary lifestyle changes and precautions to prevent falling victim to the addiction crisis. DNA4Addiction represents a significant advancement in overall wellness and combating addiction. Parents now have an invaluable resource to help protect their children. Given the prevalent use of opiates for pain management today, the importance and value of DNA4Addiction cannot be overstated.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is working to establish a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates, however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Form 8-Ks filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What is the DNA4Addiction test launched by Avalon GloboCare's Laboratory Services MSO?
How does the DNA4Addiction test work for ALBT investors?
What are the potential benefits of the DNA4Addiction test launched by Avalon GloboCare (ALBT)?
How does the DNA4Addiction test relate to the current opioid crisis mentioned in Avalon GloboCare's (ALBT) announcement?
